INTRODUCTION
Adjuvant platinum-based chemotherapy is a standard of care for patients with completely resected stage II-IIIA non-small cell lung cancer (NSCLC), with an absolute 5-year survival benefit of 4-15% in several randomized trials and meta-analyses (1) (2) (3) (4) (5) (6) (7) . However, as with most adjuvant therapies, only a subgroup of patients derives benefit from this intervention. Because chemotherapy causes both short and long term toxicities, predictive biomarkers that could identify which patients do or do not benefit would be of great clinical utility.
While previous efforts have evaluated potential predictive biomarkers of adjuvant chemotherapy benefit, most tested either single markers (8) , or considered unstratified populations consisting of squamous cell (SqCC) and adenocarcinoma (ADC) and other histologic subtypes within the spectrum of NSCLC (9, 10) . Following the completion of initial large-scale efforts to characterize the genomic and molecular alterations in NSCLC by The Cancer Genome Atlas (TCGA) consortium and others, the existence of major subsets of lung cancers with shared pathway alterations has been recognized (11). This includes ~35% of SqCC where somatic alterations resulting in activation of the NRF2 pathway via mutations or amplification of (Nuclear factor (erythroid-derived 2)-like 2) NFE2L2/NRF2 or mutation or deletion of its negative regulators Kelch like-ECH-associated protein 1 (KEAP1) or Cullin 3 (CUL3) have been identified (11).
The NRF2 transcription factor is a master regulator of the antioxidant response, and dysregulation of this pathway occurs commonly in cancer (12). Several lines of pre-clinical and clinical investigation have suggested that NRF2 pathway activation confers resistance to chemotherapy (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) . Furthermore, the available data indicate that mutations in this pathway define a major molecular subset of SqCC. However, the critical question of whether this subset of patients derives differential benefit from adjuvant chemotherapy has not been addressed. Such an analysis requires interrogation of data from the pivotal randomized clinical trials of adjuvant chemotherapy, where gene expression but not somatic mutational data are available.
While previous studies have used groups of NRF2-target genes as a readout of NRF2 activity in NSCLC (19) , and some existing gene expression signatures, including the classical expression subtype of SqCC, partially overlap with NRF2 pathway mutational status (11), no existing signature has been specifically developed a priori to identity NRF2-pathway activated SqCC.
We therefore sought to define a gene expression signature for these cancers, and to test this signature as a predictor of benefit from adjuvant chemotherapy in NCIC CTG (Clinical Trials Group) JBR.10 (4).
MATERIALS AND METHODS

Patients and datasets
This study used patient data from four independent sources: The Cancer Genome Atlas (TCGA) (11); a previously published case series of resected SqCC from Raponi et al. (GSE4573) (23); a case series of resected SqCC from the University Health Network (UHN181; GSE50081) (24); and a subset of SqCC participants in the JBR.10 clinical trial (GSE14814) (9) . For each contributing dataset, analysis was restricted to patients with SqCC for whom microarray gene expression data were available. For analysis of the TCGA dataset, only cases with microarray gene expression, and exome sequencing information available as of August 2012 were considered. Demographic and clinical information for SqCC patients in each dataset is summarized in Table 1 . Figure S1 ). Interpretation was performed blinded to other variables. 
Development of NRF2-activated (NRF2 ACT
)
Statistical analysis
Overall survival (OS) calculated from the date of surgery (Raponi, UHN) or randomization (JBR.10) to death was the primary outcome endpoint. In JBR.10, where cause of death was known, disease-specific survival was used and non-lung cancer deaths were censored at the time they occurred (9) . The survival estimates were calculated using the Kaplan-Meier method. Cox proportional hazards model was employed to test the prognostic effect of the NRF2 ACT signature as well as its predictive effect by testing its interaction with the treatment in the JBR.10 data set. The associations between categorical variables (NRF2, KEAP1, CUL3 mutations, NRF2, KEAP1 IHC with NRF2
ACT signature) were tested using Fisher's Exact Test.
The set of genes associated with the NRF2 pathway alterations were selected based on logistic regression and SAM (significance analysis of microarray) (25) . The alpha level for selection for the logistic regression was 0.001. SAM analysis was performed using a two-class, unpaired methodology to determine differential gene expression, with a set false-discovery rate of 0.05 and a call for 100 resamples to permit bootstrapping. Upon generation of a gene-set, a foldchange cutoff of 2.3 was applied to reduce the number of potential probes found to be upregulated in NRF2 or KEAP1 mutants. Statistical analyses were performed using the open source software R version 2.12.1, and the publicly available samr package.
RESULTS
NRF2
ACT signature in TCGA SqCC 104 unique SqCC cases with complete microarray gene expression, mutation, and copy number data were identified in TCGA from a total of 178 samples. Forty-one cases were found to contain somatic alterations in NRF2 (mutation or amplification); or in KEAP1 or CUL3 (mutation or deletion), and the remaining 63 cases were wild-type for these genes. Logistic regression identified 291 genes with significant differential expression (p<0.001) between somatically altered and wild-type cases (Supplemental Table S2a ). Thirty genes were found to be up- 
regulated in NRF2-altered cases by SAM analysis (Supplemental S2b). A comparison of these gene lists identified 28 overlapping genes, which define our NRF2 ACT signature (Supplemental Table S2c ). As predicted, re-clustering of the TCGA cases using the 28-gene set confirmed that NRF2 ACT identifies 2 major gene expression subgroups, with most NRF2-activating mutations segregating into the NRF2 ACT subgroup (Figure 1) .
ACT as a marker of NRF2 pathway activation.
To test the biological relevance of genes contained in the 28-gene NRF2 ACT set, we compared this list with a previously published NRF2 target gene-set defined by transcriptional analysis and CHIP-seq in NRF2 and KEAP1 knockout mouse embryonic fibroblasts (26). This analysis revealed a highly significant enrichment (one-sided p=5.96x10-11; hypergeometric test),
confirming that the 28-gene set contains bona fide NRF2 targets.
Concordance between NRF2 ACT status, NRF2/KEAP1 IHC and somatic alterations in an independent dataset
To validate the association between the NRF2 ACT signature and somatic alterations in the NRF2 pathway in SqCC, we performed hierarchical clustering using the 28-gene set, as well as NRF2
and KEAP1 mutational analysis by Sanger sequencing, in 43 SqCC from the UHN181 dataset (24) . As observed in the TCGA derivation set, NRF2 ACT identified two major subgroups in the UHN181 SqCC set, with similar proportions to TCGA (Figure 2) . Furthermore, the NRF2 ACT -high subgroup was highly enriched for tumors with somatic alterations in NRF2 (p=0.0001). In contrast, in the adenocarcinoma subset of UHN181 (n=130), NRF2 ACT did not separate tumors into discrete groups, indicating that this signature is specifically relevant to SqCC (Supplemental Figure S2 ). ACT or mutational status was observed.
Prognostic effect of NRF2 ACT in SqCC patients treated with surgery alone
No prognostic association of NRF2 ACT status was present in the UHN181 dataset of 43 patients treated with surgery alone, without adjuvant chemotherapy (HR=0.86, p=0.79; Fig 4a) .
Similarly, in a second SqCC surgery-alone dataset (Raponi, n=129), NRF2 ACT identified 2 subgroups based on gene expression (Figure 2b ), but was not significantly associated with overall survival (HR=1.43, p=0.2; Fig 4b) . A prognostic association also was absent in the observation (no adjuvant chemotherapy) arm of JBR.10 (HR=0.66, p=0.61; Fig 4c) .
Predictive effect of NRF2 ACT in SqCC patients treated with adjuvant chemotherapy
The predictive effect of NRF2 ACT recently, defined clinical approaches to lung cancer. The ultimate goal of these efforts is to identify actionable alterations that can be used to identify new therapeutic targets or refine treatment approaches for individual patients, thereby providing "personalized" or "precision" oncology and improving patient outcomes while reducing treatment-associated toxicities and costs.
The lung squamous cell carcinoma sequencing analysis has expanded the number of recognized putative "driver" oncogenes in this disease (11). These include a substantial number of recurrent but uncommon mutations in kinases, growth factor receptors and related genes that might be targetable with specific small molecule inhibitors or monoclonal antibodies, several of which currently are in clinical development (27, 28) . While it is clear that highly specific inhibitors can have dramatic efficacy when matched to tumor genotype, as in the case of EGFR-activating mutations, ALK translocations and ROS1 rearrangements in NSCLC (29) (30) (31) (32) (33) , the potential impact of somatic alterations on chemotherapy efficacy, which remains the standard of care for adjuvant treatment and the mainstay of therapy for SqCC is of additional clinical consequence.
In an effort to apply the findings of TCGA (and the work that preceded it (13, 34) ) to current clinical management, we have focused on the NRF2 pathway, which is somatically activated in over one third of SqCC (11), and has a well-characterized role in chemotherapy sensitivity based on pre-clinical studies.
Using gene expression and sequencing data from TCGA we identified a 28 gene-set (NRF2 ACT )
that is able to separate SqCC from multiple datasets into 2 subgroups. Application of NRF2
ACT in an adenocarcinoma dataset showed no similar discriminatory ability, indicating that this signature is specifically relevant for the SqCC histology, and that interrogation of the NRF2 pathway in adenocarcinoma (where KEAP1 mutations predominate) may require a similarly dedicated approach. The substantial overlap between this gene set and an independently
Research. 
derived list of genes regulated by NRF2 provided strong biological confirmation that NRF2 ACT indeed reflects transcriptional activation of this pathway. In both the TCGA derivation set and an independent SqCC series from UHN, where we performed mutational analysis for NRF2-pathway genes (NRF2, KEAP1), we observed a strong association between the presence of NRF2 pathway activating somatic alterations and NRF2 ACT -high expression status. The concordance of these findings supports the use of this gene-expression surrogate of somatic NRF2 pathway activation to test the prognostic and predictive associations of this molecular subgroup. This provides a useful tool to analyse numerous existing datasets where gene expression, but not somatic mutational data, is available. Furthermore, as a measure of downstream effects of the NRF2 transcription factor, a gene expression-based classifier may provide a more functional measure of pathway activation than mutational status alone. Indeed, it is conceivable that by capturing the set of cancers where NRF2 transcriptional activity is upregulated (whether via somatic alteration of NRF2, KEAP1 or CUL3, or by alternate mechanisms (35)), gene expression could be a superior biomarker for this purpose.
In three independent datasets of SqCC patients treated with surgery alone, we observed no significant prognostic effect of our NRF2
ACT signature. However, in keeping with our hypothesis and the pre-clinical data that supported it, we observed a trend towards differential benefit from the addition of adjuvant chemotherapy in JBR.10. These results suggest that patients with NRF2-activating somatic alterations may not benefit from adjuvant chemotherapy, possibly due to intrinsic chemo-resistance conferred by activation of the NRF2 transcriptional program. This finding is consistent with data from other cohort studies and case series in several tumor types, including NSCLC and esophageal cancer, even though different methods to assess NRF2 activation were used (14, 17) . To our knowledge, ours is the first to evaluate a predictive marker of NRF2 activation in the setting of a randomized trial with an untreated control arm.
